CSL Shares Edge Higher Amid Analyst Skepticism and Seqirus Uncertainty
CSL Limited's shares ROSE marginally to A$174.57 on 18 December 2025, buoyed by buybacks but constrained by persistent market doubts. Analyst downgrades and unclear guidance overshadow the stock's defensive healthcare reputation, with Seqirus vaccine demand volatility and political scrutiny amplifying uncertainty.
While plasma collection trends and gene therapy pipelines remain long-term strengths, FY26 earnings visibility is clouded by cost pressures and geopolitical risks. The market's patience for a fundamental rebound is being tested as institutional investors await concrete recovery signals.